Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin for chronic cough in CANVAS
ACTRN12623001356651Phase 3Not yet recruiting
- Sponsor
- Richard Roxburgh
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pregabalin in Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) and chronic cough (2 arms), sponsored by Richard Roxburgh. Primary endpoint: Reduction in cough frequency. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
pregabalin
03
Conditions
Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS)chronic cough
Beyond the preview
Go deeper on ACTRN12623001356651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623001356651.